In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO)
Abstract Data of thoracic in-field reirradiation with two courses of stereotactic body radiotherapy (SBRT) is scarce. Aim of this study is to investigate feasibility and safety of this approach. Patients with a second course of thoracic SBRT and planning target volume (PTV) overlap were analyzed in...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/97e6418881f24744aa53063fb62cee62 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:97e6418881f24744aa53063fb62cee62 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:97e6418881f24744aa53063fb62cee622021-12-02T11:35:57ZIn-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO)10.1038/s41598-021-83210-32045-2322https://doaj.org/article/97e6418881f24744aa53063fb62cee622021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83210-3https://doaj.org/toc/2045-2322Abstract Data of thoracic in-field reirradiation with two courses of stereotactic body radiotherapy (SBRT) is scarce. Aim of this study is to investigate feasibility and safety of this approach. Patients with a second course of thoracic SBRT and planning target volume (PTV) overlap were analyzed in this retrospective, multicenter study. All plans and clinical data were centrally collected. 27 patients from 8 centers have been amenable for evaluation: 12 with non-small-cell lung cancer, 16 with metastases, treated from 2009 (oldest first course) to 2020 (latest second course). A median dose of 38.5 Gy to the 65%-isodose over a median of 5 fractions was prescribed in the first course and 40 Gy in 5 fractions for the second SBRT-course. Median PTV of the second SBRT was 29.5 cm3, median PTV overlap 22 cm3. With a median interval of 20.2 months between the two SBRT-courses, 1-year OS, and -LCR were 78.3% and 70.3% respectively. 3 patients developed grade 1 and one grade 2 pneumonitis. No grade > 2 toxicity was observed. Peripheral location and dose were the only factors correlating with tumor control. A second SBRT-course with PTV overlap appears safe and achieves reasonable local control.Caroline JohnRiccardo Dal BelloNicolaus AndratschkeMatthias GuckenbergerJudit Boda-HeggemannEleni GkikaFrederick MantelHanno M. SpechtCarmen StrombergerFranz ZehentmayrOliver BlanckPanagiotis BalermpasNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Caroline John Riccardo Dal Bello Nicolaus Andratschke Matthias Guckenberger Judit Boda-Heggemann Eleni Gkika Frederick Mantel Hanno M. Specht Carmen Stromberger Franz Zehentmayr Oliver Blanck Panagiotis Balermpas In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO) |
description |
Abstract Data of thoracic in-field reirradiation with two courses of stereotactic body radiotherapy (SBRT) is scarce. Aim of this study is to investigate feasibility and safety of this approach. Patients with a second course of thoracic SBRT and planning target volume (PTV) overlap were analyzed in this retrospective, multicenter study. All plans and clinical data were centrally collected. 27 patients from 8 centers have been amenable for evaluation: 12 with non-small-cell lung cancer, 16 with metastases, treated from 2009 (oldest first course) to 2020 (latest second course). A median dose of 38.5 Gy to the 65%-isodose over a median of 5 fractions was prescribed in the first course and 40 Gy in 5 fractions for the second SBRT-course. Median PTV of the second SBRT was 29.5 cm3, median PTV overlap 22 cm3. With a median interval of 20.2 months between the two SBRT-courses, 1-year OS, and -LCR were 78.3% and 70.3% respectively. 3 patients developed grade 1 and one grade 2 pneumonitis. No grade > 2 toxicity was observed. Peripheral location and dose were the only factors correlating with tumor control. A second SBRT-course with PTV overlap appears safe and achieves reasonable local control. |
format |
article |
author |
Caroline John Riccardo Dal Bello Nicolaus Andratschke Matthias Guckenberger Judit Boda-Heggemann Eleni Gkika Frederick Mantel Hanno M. Specht Carmen Stromberger Franz Zehentmayr Oliver Blanck Panagiotis Balermpas |
author_facet |
Caroline John Riccardo Dal Bello Nicolaus Andratschke Matthias Guckenberger Judit Boda-Heggemann Eleni Gkika Frederick Mantel Hanno M. Specht Carmen Stromberger Franz Zehentmayr Oliver Blanck Panagiotis Balermpas |
author_sort |
Caroline John |
title |
In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO) |
title_short |
In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO) |
title_full |
In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO) |
title_fullStr |
In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO) |
title_full_unstemmed |
In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO) |
title_sort |
in-field stereotactic body radiotherapy (sbrt) reirradiation for pulmonary malignancies as a multicentre analysis of the german society of radiation oncology (degro) |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/97e6418881f24744aa53063fb62cee62 |
work_keys_str_mv |
AT carolinejohn infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT riccardodalbello infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT nicolausandratschke infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT matthiasguckenberger infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT juditbodaheggemann infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT elenigkika infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT frederickmantel infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT hannomspecht infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT carmenstromberger infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT franzzehentmayr infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT oliverblanck infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro AT panagiotisbalermpas infieldstereotacticbodyradiotherapysbrtreirradiationforpulmonarymalignanciesasamulticentreanalysisofthegermansocietyofradiationoncologydegro |
_version_ |
1718395834284900352 |